# US 10,864,152 B2 · TRPV3 agonists for the treatment of skin conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,152 B2
- Document ID: US10864152B2
- Status: Granted
- Kind: B2
- Application number: 15/704,581
- Filed: 2017-09-14
- Published: 2018-03-29
- Granted: 2020-12-15
- Earliest claimed: 2012-09-14
- Assignees: Soricimed Biopharma Inc.
- Applicants: John M. Stewart
- Inventors: John M. Stewart
- Web page: https://patentgrep.com/patent/US10864152B2

## CPC

- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/47: from mammals
- C07K 14/4747: {Apoptosis related proteins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described are methods and uses of TRPV3 agonists for the treatment of conditions associated with TRPV3 pathophysiology such as acne, psoriasis, dermatitis, would healing, the inhibition of hair growth, anxiety or depression. Peptides comprising all or part of the C-terminal portion of soricidin are shown to activate TRPV3 cation channel activity and/or promote wound healing in keratinocytes.

## Claims

### Claim 1

A method of promoting skin repair in a subject in need thereof comprising administering a topical formulation comprising a peptide consisting of 7, 8, or 9 contiguous amino acids of SEQ ID NO: 4 and an emollient to the skin of the subject in an amount that promotes the migration and/or proliferation of keratinocytes in the skin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the formulation is administered to a cut, abrasion, or laceration in the subject's skin.

### Claim 3 (depends on 1)

The method of claim 1 wherein the peptide consists of SEQ ID NO: 4.

### Claim 4 (depends on 1)

The method of claim 1 wherein the peptide consists of SEQ ID NO: 5.

### Claim 5 (depends on 1)

The method of claim 1 wherein the formulation further comprises an alpha-hydroxy acid.

### Claim 6 (depends on 5)

The method of claim 5 wherein the alpha-hydroxy acid is glycolic acid.